Placebo Administration

Phase 1

RRoswell Park Cancer Institute

Placebo Administration is one of 23 therapeutic programs targeting Cannabis Dependence. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Cannabis DependenceNot yet recruiting

Recurrent Glioblastoma IDH WildtypeRecruiting

Cannabis DependencePhase 1

Not yet recruiting

Recurrent Glioblastoma IDH WildtypePreclinical

Recruiting

Competition

Competitive Landscape

20 competitors in Cannabis Dependence

#DrugCompanyPhaseTrials

Nicorette

Pfizer

Approved

1 2

Cysteine Hydrochloride

Novartis

Approved

1 3

Rozerem

Revia

Buspar

Viibryd

Lioresal

Epidiolex

Klonopin

EEngelhard Arzneimittel GmbH & Co.KG

Approved

—10

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Erythroplakia

NCT05237960

Q1 2027

Phase 1Recruiting

Hematopoietic and Lymphoid Cell Neoplasm

NCT06184321

Q2 2027

Phase 2Recruiting

Prostate Adenocarcinoma

NCT06022822

PreclinicalRecruiting

Recurrent Glioblastoma IDH Wildtype

NCT05432804

Phase 2Recruiting

Advanced Malignant Solid Neoplasm

NCT05705492

Q3 2027

Phase 1Recruiting

Advanced Ovarian Carcinoma

NCT07144826

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia3 trials

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05564390·2,000 enrolled

A Two Cohort, Randomized, Double-Blind, Placebo-Controlled, Phase II Multi-Center Signal-Finding Study of Venetoclax Combined With Reduced-Intensity Conditioning Followed by Allogeneic Hematopoietic Cell Transplantation Then Venetoclax Maintenance in Adult Patients With Acute Myeloid Leukemia in First Complete Remission: A MyeloMATCH Sub-Study

Not yet recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06954987·244 enrolled

A Randomized Double-Blinded Trial of Xylitol Dental Wipes for the Prophylaxis of Bloodstream Infections From Oral Organisms in Pediatric Patients With Acute Myeloid Leukemia

Recruiting·CChildren's Oncology Group·Phase 3·NCT07022678·556 enrolled

Barrett Esophagus2 trials

Repurposing Itraconazole for Secondary Prevention of Metaplasia and Primary Prevention of Cancer in Patients With High-risk Barrett's Esophagus in Combination With Ablation

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06732388·76 enrolled

Obeticholic Acid for Prevention in Barrett's Esophagus

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04939051·30 enrolled

Prostate Carcinoma2 trials

A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers

Active, not recruiting·EECOG-ACRIN Cancer Research Group·Phase 2·NCT04597359·360 enrolled

A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)

Active, not recruiting·EECOG-ACRIN Cancer Research Group·Phase 3·NCT04484818·27 enrolled

Advanced Malignant Solid Neoplasm2 trials

Treatment of Immune Related Adverse Events With CD24Fc (TIRAEC)

Terminated·TTianhong Li·Preclinical·NCT04552704·3 enrolled

ACTO: A Phase II, Randomized, Placebo-Controlled Study Evaluating Olanzapine in the Management of Cancer Cachexia

Recruiting·OOHSU Knight Cancer Institute·Phase 2·NCT05705492·66 enrolled

Recurrent Glioblastoma IDH Wildtype1 trial

A Phase 1 and Randomized Phase 2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma

Recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT05432804·97 enrolled

22 more indications

Chronic Graft Versus Host Disease1 trial

Randomized Phase II Study of Belumosudil vs. Placebo for Preemptive Treatment of Chronic Graft Versus Host Disease

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT05996627·82 enrolled

Pancreatic Acinar Cell Carcinoma1 trial

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04858334·152 enrolled

Anatomic Stage IV Breast Cancer AJCC v81 trial

An Early Phase and Phase II Clinical Trial to Evaluate Ganglioside-Monosialic Acid (GM1) for Preventing Paclitaxel-Associated Neuropathy

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 2·NCT05751668·7 enrolled

Cutaneous Melanoma1 trial

A Phase II Double-Blind Trial of Sulforaphane for Therapeutic Prevention of Melanoma in Patients With Multiple Atypical Nevi and a Prior History of Melanoma

Recruiting·EEastern Cooperative Oncology Group·Phase 2·NCT07040280·120 enrolled

Hematopoietic and Lymphatic System Neoplasm1 trial

Phase II Double-Blinded Placebo-Controlled Randomized Trial of CSF-1R Inhibitor, Axatilimab for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation (ABRAXAS)

Withdrawn·MMayo Clinic·Phase 2·NCT07349771

Erythroplakia1 trial

M4OC-Prevent 2.0: Phase IIb Trial of Metformin for Oral Cancer Prevention

Active, not recruiting·UUniversity of Arizona·Phase 2·NCT05237960·34 enrolled

Astrocytoma, IDH-Mutant, Grade 31 trial

Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination With the IDH Inhibitor Vorasidenib vs Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas

Recruiting·AAlliance for Clinical Trials in Oncology·Phase 3·NCT07215910·408 enrolled

Insomnia1 trial

MC251001 - Phase II Randomized Double-Blinded Pilot Study of THC vs. THC/CBD (1:1) vs. Placebo for Insomnia in Patients With Cancer

Not yet recruiting·MMayo Clinic·Phase 2·NCT07565974·69 enrolled

Prostate Adenocarcinoma1 trial

A Phase 2 Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06022822·90 enrolled

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v81 trial

A Randomized, Masked, Placebo Controlled, Phase II Trial Of Concurrent Chemoradiation With BMX-001 In Patients With Head And Neck Squamous Cell Carcinoma Receiving Concurrent Chemoradiation

Recruiting·NNRG Oncology·Phase 2·NCT06532279·98 enrolled

Advanced Ovarian Carcinoma1 trial

A Randomized, Double-Blind, Placebo Controlled, Study to Investigate Efficacy of a Probiotic Intervention on the Gut and Vaginal Microbiome of Ovarian Cancer Patients Undergoing Treatment With Platinum Chemotherapy

Recruiting·OOhio State University Comprehensive Cancer Center·Phase 1·NCT07144826·161 enrolled

Hematopoietic and Lymphoid Cell Neoplasm1 trial

A Randomized Trial of Alteplase Versus Placebo Through an Indwelling Pleural Catheter for Management of Symptomatic Septated MPE

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06184321·30 enrolled

Oligometastatic Prostate Carcinoma1 trial

A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)

Active, not recruiting·NNRG Oncology·Phase 2·NCT05053152·194 enrolled

Stricture1 trial

Perioperative Use of Dexmedetomidine-esketamine Combination on Depression and Anxiety in Patients Undergoing Laparoscopic Ureteral Reconstruction: a Randomized Controlled Trial

Not yet recruiting·PPeking University First Hospital·Approved·NCT07753772·658 enrolled

Cannabis Dependence1 trial

Acute Effects of Sequential Nicotine Vaping on the Pharmacokinetic and Pharmacodynamic Properties of Vaped THC: A Double-Blind, Placebo-Controlled, Randomized Within-Subject Crossover Study

Not yet recruiting·RRoswell Park Cancer Institute·Phase 1·NCT06334016·60 enrolled

Clinical Stage IV Cutaneous Melanoma AJCC v81 trial

The BAMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib With or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma With Elevated LDH

Terminated·EECOG-ACRIN Cancer Research Group·Phase 2·NCT04527549·5 enrolled

Melanoma1 trial

A Randomized Phase II Trial of Adjuvant Nivolumab With or Without Cabozantinib in Patients With Resected Mucosal Melanoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05111574·101 enrolled

Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v81 trial

A Phase II Randomized Placebo-Controlled Study of Fisetin and Exercise to Prevent Frailty in Breast Cancer Survivors

Recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT06113016·164 enrolled

Anatomic Stage I Breast Cancer AJCC v81 trial

A Phase II Randomized Double-Blind Placebo-Controlled Study of Fisetin to Improve Physical Function in Breast Cancer Survivors

Recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT05595499·88 enrolled

Cigarette Smoking-Related Carcinoma1 trial

Phase II Randomized, Double Blind, Placebo-Controlled Trial of Broccoli Seed and Sprout Extract (BSSE), Avmacol ES, to Evaluate Sustained Detoxification of Tobacco Carcinogens in Heavy Smokers

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05121051·135 enrolled

Anatomic Stage 0 Breast Cancer AJCC v81 trial

High Cannabidiol (CBD) Standardized Extract for Aromatase Inhibitor-Induced Arthralgia - A Randomized Controlled Double Blind Clinical Trial

Suspended·CCity of Hope Medical Center·Phase 2·NCT06538389·36 enrolled

Central Nervous System Cancer1 trial

A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT04939597·162 enrolled

Sources

References

[1]
ClinicalTrials.gov — 32 trial records for Placebo Administration. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Placebo Administration. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Roswell Park Cancer Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: RRoswell Park Cancer Institute

Placebo Administration

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q3 2027

Trials by Indication[1]

Acute Myeloid Leukemia3 trials

Barrett Esophagus2 trials

Prostate Carcinoma2 trials

Advanced Malignant Solid Neoplasm2 trials

Recurrent Glioblastoma IDH Wildtype1 trial

Chronic Graft Versus Host Disease1 trial

Pancreatic Acinar Cell Carcinoma1 trial

Anatomic Stage IV Breast Cancer AJCC v81 trial

Cutaneous Melanoma1 trial

Hematopoietic and Lymphatic System Neoplasm1 trial

Erythroplakia1 trial

Astrocytoma, IDH-Mutant, Grade 31 trial

Insomnia1 trial

Prostate Adenocarcinoma1 trial

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v81 trial

Advanced Ovarian Carcinoma1 trial

Hematopoietic and Lymphoid Cell Neoplasm1 trial

Oligometastatic Prostate Carcinoma1 trial

Stricture1 trial

Cannabis Dependence1 trial

Clinical Stage IV Cutaneous Melanoma AJCC v81 trial

Melanoma1 trial

Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v81 trial

Anatomic Stage I Breast Cancer AJCC v81 trial

Cigarette Smoking-Related Carcinoma1 trial

Anatomic Stage 0 Breast Cancer AJCC v81 trial

Central Nervous System Cancer1 trial

References

Drug Info

Quick Facts

Related News